Table 3 Characteristics of respondents (n=80) stratified by site
From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
| Â | All | China | Japan | South Korea | Taiwan | p-value |
|---|---|---|---|---|---|---|
Primary Role, % | ||||||
Clinicians | 60.0 | 15.0 | 15.0 | 15.0 | 15.0 | 0.196 |
Hepatologist | 18.8 | 2.5 | 5.0 | 7.5 | 3.8 | Â |
Oncologist | 21.3 | 10.0 | 2.5 | 1.3 | 7.5 | Â |
Radiologist | 3.8 | 1.3 | 1.3 | 1.3 | 0.0 | Â |
Surgeon | 12.5 | 0.0 | 8.3 | 4.2 | 0.0 | Â |
Other | 3.8 | 0.4 | 1.1 | 1.1 | 1.1 | Â |
Policy makers | 25.0 | 6.3 | 6.3 | 6.3 | 6.3 | 0.167 |
Governmental | 18.8 | 5.0 | 6.3 | 5.0 | 2.5 | Â |
Non-Governmental | 6.3 | 1.3 | 0.0 | 1.3 | 3.8 | Â |
Advocates | 15.0 | 3.8 | 3.8 | 3.8 | 3.8 | 0.518 |
Disease advocacy | 5.0 | 0.0 | 1.3 | 1.3 | 2.5 | Â |
Media/Spokesperson | 3.8 | 1.3 | 1.3 | 0.0 | 1.3 | Â |
Patient advocacy | 6.3 | 2.5 | 1.3 | 2.5 | 0.0 | Â |
Area of Involvement, % | Â | Â | Â | Â | Â | 0.002** |
Hepatitis | 26.3 | 5.0 | 11.3 | 3.8 | 6.3 | Â |
HCC | 57.5 | 17.5 | 13.7 | 16.3 | 10.0 | Â |
Metastatic liver cancer | 10.0 | 2.5 | 0.0 | 0.0 | 7.5 | Â |
Transplantation | 6.3 | 0.0 | 0.0 | 5.0 | 1.3 | Â |
Level of Involvement, % | Â | Â | Â | Â | Â | 0.029* |
International | 15.0 | 3.8 | 3.8 | 5.0 | 2.5 | Â |
Local/municipality | 6.3 | 5.0 | 0.0 | 1.3 | 0.0 | Â |
National | 56.3 | 13.7 | 11.3 | 17.5 | 13.7 | Â |
Regional/provincial | 22.5 | 2.5 | 10.0 | 1.3 | 8.8 | Â |